The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Second-line treatment strategies for patients with relapsed DLBCL
Mariana Bastos, MD, PhD, Gregorio Marañón University General Hospital, Madrid, Spain, discusses second-line treatment strategies for patients with relapsed diffuse large B-cell lymphoma (DLBCL). She notes that high-risk and early-relapsing patients should be focused on, with CAR-T therapy as the standard of care for eligible individuals. Those with late relapse typically undergo autologous stem cell transplantation (autoSCT). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
After frontline treatment, we know that near 40% of patients have a relapse. We need to focus on higher-risk patients that are those with a high IPI, or those patients that, for example, after four cycles have a positive PET interim. That group of patients will need a rescue in second line, and in second line currently the paradigm of treatment has changed. So we need to focus on those patients that have an early relapse and early relapse is considered those patients that have a relapse during the 12 first months after the induction treatment...
After frontline treatment, we know that near 40% of patients have a relapse. We need to focus on higher-risk patients that are those with a high IPI, or those patients that, for example, after four cycles have a positive PET interim. That group of patients will need a rescue in second line, and in second line currently the paradigm of treatment has changed. So we need to focus on those patients that have an early relapse and early relapse is considered those patients that have a relapse during the 12 first months after the induction treatment. And currently the standard of care is CAR-T in the countries where CAR-T is available. And we need to think about if the patient is or not candidate to CAR T-cell therapy. For those patients that are not candidates, we have another combination with antibodies that could be polatuzumab and tafasitamab. And then we have the challenge of the late relapses that are still treated with autologous transplant.
Read more...
Disclosures
Consultancy: Abbvie, Astra-Zeneca, BMS/Celgene, Incyte, Kite, Novartis, Roche, Takeda; Research Funding: Roche, Kite, AMHH, SEHH, IiCIII; Honoraria: Abbvie, BMS/Celgene, Incyte, Kite, Novartis, Roche, Takeda.
